Citadel Advisors LLC 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:20 pm Sale |
2024-09-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Citadel Advisors LLC | 2,737,221 3.900% |
-1,001,261 (-26.78%) |
Filing |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Citadel Advisors LLC | 3,738,482 5.300% |
-101,347 (-2.64%) |
Filing |
| 2023-11-17 5:12 pm Purchase |
2023-11-07 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Citadel Advisors LLC | 3,839,829 5.400% |
2,335,959 (+155.33%) |
Filing |
| 2021-02-16 4:30 pm Sale |
2020-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Citadel Advisors LLC | 1,503,870 3.700% |
-626,094 (-29.39%) |
Filing |